Related Experiment Videos
Botulinum toxin therapy for limb dystonias
D M Yoshimura1, M J Aminoff, R K Olney
1Department of Neurology, School of Medicine, University of California, San Francisco 94143-0114.
Neurology
|March 1, 1992
Summary
Botulinum toxin injections provided subjective improvement for most limb dystonia patients, with 82% experiencing benefits lasting months. However, objective measures did not confirm these improvements, and transient weakness was a common side effect.
Area of Science:
- Neurology
- Clinical Medicine
- Pharmacology
Background:
- Limb dystonias encompass various conditions causing involuntary muscle contractions.
- Botulinum toxin is a potential therapeutic agent for focal muscle overactivity.
Purpose of the Study:
- To evaluate the efficacy and safety of botulinum toxin for limb dystonias.
- To compare subjective patient reports with objective clinical assessments.
Main Methods:
- A placebo-controlled, blinded study involving 17 patients with different types of limb dystonia.
- Electromyography (EMG) guided muscle identification and assessment.
- Graded doses of botulinum toxin administered and compared to placebo.
Main Results:
- Subjective improvement reported in 53% of botulinum toxin injections and 82% of patients.
- Improvements lasted 1 to 4 months, with similar response rates across dystonia types.
- Objective evaluations did not show significant improvement compared to placebo.
- Transient focal weakness occurred in 53% of toxin injections.
Conclusions:
- Botulinum toxin offers subjective symptom relief for many limb dystonia patients.
- Objective efficacy remains unproven, and side effects like weakness are common.
- Further research may be needed to correlate subjective and objective outcomes.